Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial
Abstract
1. Introduction
2. Materials and Methods
2.1. Animals and Inclusion Criteria
2.2. Antioxidant Supplementation and Medical Treatment
2.3. Standardized Monitoring of Clinical Signs and Symptoms and MMI-SE
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Peterson, M.E. Animal models of disease: Feline hyperthyroidism: An animal model for toxic nodular goiter. J. Endocrinol. 2014, 223, T97–T114. [Google Scholar] [CrossRef] [PubMed]
- Marcocci, C.; Leo, M.; Altea, M.A. Oxidative stress in Graves’ disease. Eur. Thyroid J. 2012, 1, 80–87. [Google Scholar] [CrossRef] [PubMed]
- Mancini, A.; Di Segni, C.; Raimondo, S.; Olivieri, G.; Silvestrini, A.; Meucci, E.; Currò, D. Thyroid hormones, oxidative stress, and inflammation. Med. Inflam. 2016. [Google Scholar] [CrossRef] [PubMed]
- Candellone, A.; Gianella, P.; Ceccarelli, L.; Raviri, G.; Badino, P.; Roncone, S.; Kooistra, H.S.; Meineri, G. Redox unbalance in the hyperthyroid cat: A comparison with healthy and non-thyroidal diseased cats. BMC Vet. Res. 2019, 159, 136. [Google Scholar] [CrossRef] [PubMed]
- Daminet, S.; Kooistra, H.S.; Fracassi, F.; Graham, P.A.; Hibbert, A.; Lloret, A.; Mooney, C.T.; Neiger, R.; Rosenberg, D.; Syme, H.M.; et al. Best practice for the pharmacological management of hyperthyroid cats with antithyroid drugs. J. Small Anim. Pract. 2014, 55, 4–13. [Google Scholar] [CrossRef] [PubMed]
- Heidari, R.; Niknahad, H.; Jamshidzadeh, A.; Abdoli, N. Factors affecting drug-induced liver injury: Antithyroid drugs as instances. Clin. Mol. Hepatol. 2014, 20, 237–248. [Google Scholar] [CrossRef]
- Heidari, R.; Niknahad, H.; Jamshidzadeh, A.; Eghbal, M.A.; Abdoli, N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv. Pharm. Bull. 2015, 5, 1–11. [Google Scholar]
- Farzei, M.H.; Zobeiri, M.; Parvizi, F.; El-Senduny, F.F.; Marmouzi, I.; Coy-Barrera, E.; Naseri, R.; Nabavi, S.M.; Rahimi, R.; Abdollahi, M. Curcumin in liver disease: A systematic review of the cellular mechanism of oxidative stress and clinical perspective. Nutrients 2018, 10, 855. [Google Scholar] [CrossRef]
- Kocaadam, B.; Şanlier, N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit. Rev. Food Sci. Nutr. 2017, 57, 2889–2895. [Google Scholar] [CrossRef]
- Ferreira, A.C.; Lisboa, P.C.; Oliveira, K.J.; Lima, L.P.; Barros, I.A.; Carvalho, D.P. Inhibition of thyroid type 1 deiodinase activity by flavonoids. Food Chem. Toxicol. 2002, 40, 913–917. [Google Scholar] [CrossRef]
- Lund, J.C.; Pantuso, T. Combination Effects of Quercetin, Resveratrol and Curcumin on in Vitro Intestinal Absorption. J. Restor. Med. 2014, 3, 112–120. [Google Scholar] [CrossRef]
- Venditti, P.; Di Stefano, L.; Di Meo, S. Vitamin E management of oxidative damage-linked dysfunctions of hyperthyroid tissues. Cell Mol. Life Sci. 2013, 70, 3125–3144. [Google Scholar] [CrossRef] [PubMed]
- Nussbaum, L.K.; Scavelli, T.D.; Scavelli, D.M.; Pintar, J.; Henderson, A.K.; DeMarco, J.A.; Worwag, S.; Bastian, R.P.; Kittner, H.S. Abdominal ultrasound examination findings in 534 hyperthyroid cats referred for radioiodine treatment between 2007–2010. J. Vet. Intern. Med. 2015, 29, 1069–1073. [Google Scholar] [CrossRef]
- Rodan, I.; Sundahl, E.; Carney, H.; Gagnon, A.C.; Heath, S.; Landsberg, G.; Seksel, K.; Yin, S. AAFP and ISFM feline-friendly handling guidelines. J. Feline Med. Surg. 2011, 13, 364–375. [Google Scholar] [CrossRef]
- International Renal Interest Society (IRIS). CKD Staging in Cats. IRIS Staging of CKD 2015. Available online: http://www.iris-kidney.com/pdf/003-5559.001-iris-website-staging-of-ckd-pdf_220116-final.pdf#page=7 (accessed on 13 July 2016).
- Branter, E.; Drescher, N.; Padilla, M.; Trepanier, L.A. Antioxidant status in hyperthyroid cats before and after radioiodine treatment. J. Vet. Intern. Med. 2012, 26, 582–588. [Google Scholar] [CrossRef]
- Candellone, A.; Girolami, F.; Carfora, I.; Nebbia, C.; Meineri, G.; Odore, R.; Badino, P. Effects of natural antioxidants on methimazole-induced cytotoxicity in a feline kidney cell line (CFRK). In Proceedings of the 14th International Congress of EAVPT, Wroklaw, Poland, 24–27 June 2018. [Google Scholar]
- WSAVA Global Nutrition Committee. Body Condition Score. In WSAVA Nutritional Guidelines. 2013. Available online: http://www.wsava.org/WSAVA/media/PDF_old/Body-condition-score-chart-cats.pdf (accessed on 13 July 2016).
- Norsworthy, G.D.; Adams, V.J.; McElhaney, M.R.; Milios, J.A. Relationship between semi-quantitative thyroid palpation and total thyroxine concentration in cats with and without hyperthyroidism. J. Feline Med. Surg. 2002, 4, 139–143. [Google Scholar] [CrossRef]
- Veterinary Cooperative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet. Compar. Oncol. 2016, 14, 417–446. [Google Scholar] [CrossRef]
- Scott-Moncrieff, J.C. Feline Hyperthyroidism. In Canine and Feline Endocrinology, 4th ed.; Feldman, E.C., Nelson, R., Reusch, C., Scott-Moncrieff, J.C., Eds.; Saunders: Philadelphia, PA, USA, 2015; pp. 136–190. [Google Scholar]
- Lecuyer, M.; Prini, S.; Dunn, M.E.; Doucet, M.Y. Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism. Can. Vet. J. 2006, 47, 131–135. [Google Scholar]
- Sartor, L.L.; Trepanier, L.A.; Kroll, M.M.; Rodan, I.; Challoner, L. Efficacy and safety of transdermal methimazole in the treatment of cats with hyperthyroidism. J. Vet. Intern. Med. 2004, 18, 651–655. [Google Scholar] [CrossRef]
- Trepanier, L.A.; Hoffmann, S.B.; Kroll, M.; Rodan, I.; Challoner, L. Efficacy and safety of once versus twice daily administration of methimazole in cats with hyperthyroidism. J. Am. Vet. Med. Assoc. 2003, 222, 954–958. [Google Scholar] [CrossRef]
- Boretti, F.S.; Sieber-Ruckstuhl, N.S.; Schäfer, S.; Gerber, B.; Baumgartner, C.; Riond, B.; Hofmann-Lehmann, R.; Reusch, C.E. Transdermal application of methimazole in hyperthyroid cats: A long-term follow-up study. J. Feline Med. Surg. 2014, 16, 453–459. [Google Scholar] [CrossRef] [PubMed]
- Panda, S.; Kar, A. Annona squamosa seed extract in the regulation of hyperthyroidism and lipid-peroxidation in mice: Possible involvement of quercetin. Phytomedicine 2007, 14, 799–805. [Google Scholar] [CrossRef] [PubMed]
- FEDIAF Nutritional Guidelines for Complete and Complementary Pet Food for Cats and Dogs. 2018. Available online: http://www.fediaf.org/self-regulation/nutrition/ (accessed on 11 March 2019).
Antioxidant Compound * | Dose in 1mL of Paste |
---|---|
Curcumin | 100 mg |
Quercetin | 40 mg |
Resveratrol | 1.5 mg |
Vitamin E | 15 mg |
Clinical pathological Features | Parameters | Group M (n = 14) | Group M+A (n = 16) | Reference Interval |
---|---|---|---|---|
Signalment | Age (years) | 12.8 ± 2.4 | 12.9 ± 2 | / |
Breed (n) | DSH 9; DLH 3; PERS 1; CHART 1 | DSH 11; DLH 1; PERS 1 | / | |
Gender (n) | MC 6; FN 8 | MC 6; FN 10 | / | |
Body Weight (kg) | 3.9 ± 0.7 | 4.0 ± 0.8 | / | |
BCS | 4 ± 0.5 | 4 ± 0.5 | 0-9 | |
Hemato-biochemical values | RBC (×106 /uL) | 6.6 ± 1.3 | 6.5 ± 1.1 | 4.6–10 |
Htc (%) | 34.2 ± 6.7 | 31.6 ± 6.2 | 28–49 | |
WBC (×103 /uL) | 11.5 ± 5.3 | 11 ± 4.5 | 5.5–19.5 | |
Alb (g/dL) | 3 ± 0.8 | 3.3 ± 0.8 | 2.2–4.4 | |
BUN (mg/dL) | 22.7 ± 5.8 | 23 ± 5.8 | 10–30 | |
CREA (mg/dL) | 1.3 ± 0.3 | 1.3 ± 0.3 | 0.3–1.6 | |
ALT (UI/L) | 93.7 ± 23 | 92.1 ± 22.1 | 20–100 | |
AST (UI/L) | 89 ± 27 | 91 ± 18 | 10–100 | |
ALP (UI/L) | 42 ± 8.4 | 39 ± 9.6 | 10–50 | |
Phos (mg/dL) | 4.8 ± 1.5 | 5 ± 1.9 | 2.4–8.2 | |
Urinary SG | 1039 ± 14 | 1041 ± 12.1 | >1035 | |
Thyroid function | tT4 (µg/dL) | 10 ± 3.4 | 10.3 ± 3.7 | 0.8–4.3 |
Clinical scores | OHCCS | 16.1 ± 7.4 | 16.4 ± 7.4 | 0–35 |
VHCCS | 12.1 ± 4 | 12.6 ± 5.7 | 0–30 | |
Redox unbalance | dROMs (CarrU) | 175.8 ± 2.2 | 175.3 ± 2.6 | <104 * |
OXY-Adsorbent (µmol HClO/mL) | 301.4 ± 84 | 321 ± 115 | >390 * | |
OSi (CarrU/µmol HClO/mL) | 0.66 ± 0.3 | 0.66 ± 0.3 | <0.27 * |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Candellone, A.; Badino, P.; Gianella, P.; Girolami, F.; Raviri, G.; Saettone, V.; Meineri, G. Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial. Antioxidants 2020, 9, 15. https://doi.org/10.3390/antiox9010015
Candellone A, Badino P, Gianella P, Girolami F, Raviri G, Saettone V, Meineri G. Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial. Antioxidants. 2020; 9(1):15. https://doi.org/10.3390/antiox9010015
Chicago/Turabian StyleCandellone, Alessia, Paola Badino, Paola Gianella, Flavia Girolami, Graziella Raviri, Vittorio Saettone, and Giorgia Meineri. 2020. "Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial" Antioxidants 9, no. 1: 15. https://doi.org/10.3390/antiox9010015
APA StyleCandellone, A., Badino, P., Gianella, P., Girolami, F., Raviri, G., Saettone, V., & Meineri, G. (2020). Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial. Antioxidants, 9(1), 15. https://doi.org/10.3390/antiox9010015